FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2770760027> ?p ?o ?g. }

• W2770760027 endingPage "x114" @default.
• W2770760027 startingPage "x114" @default.
• W2770760027 abstract "Background: Uveal melanoma is a distinct subtype of melanoma. Several previously reported studies showed that anti-PD-1 or PD-L1 antibodies, which are efficacious for cutaneous melanoma with tolerable toxicities, had only limited activities on metastatic uveal melanoma. However, since most of the patients in those studies were previously treated with ipilimumab, the efficacy of anti-PD-1 antibody when it is used prior to ipilimumab for metastatic uveal melanoma is less clear. Methods: To evaluate the efficacy of nivolumab for Asian patients with metastatic uveal melanoma previously untreated with ipilimumab, we carried out a retrospective study using a database of National Cancer Center Hospital, Tokyo, Japan, in which nivolumab was approved one year earlier than ipilimumab. As clinical efficacy outcomes, best overall response which was evaluated by RECIST 1.1, progression-free survival (PFS), and overall survival (OS) were determined. Results: We identified 14 patients with metastatic uveal melanoma who received nivolumab at a dosage of 3mg/kg every 2 weeks or 2mg/kg every 3 weeks. Median age was 59.5 (range, 42 - 74), and 11 patients were male. Performance status was 0 in 9 patients and 1 in 5 patients. All the patients had liver metastases and 9 patients had additional extrahepatic metastases. At baseline, serum lactate dehydrogenase (LDH) was elevated in 8 patients. Although 8 patients had previous treatment history of transarterial chemoembolization (TACE), none of the 14 patients had received any prior systemic therapies including ipilimumab. Of 12 evaluable patients, objective tumor response was observed in 1 patient for an overall response rate of 8.3%, and stable disease was observed in 5 patients. The median PFS was 10 weeks (range, 4 – 94 weeks), and the median OS was 58 weeks (range, 5 – 105 weeks). Conclusions: Even though nivolumab is used prior to ipilimumab, metastatic uveal melanoma seems to be still refractory to nivolumab monotherapy. However, since one patient in our cohort achieved objective response, treatment strategies in combination with anti-PD1 antibody should be further investigated. Legal entity responsible for the study: National Cancer Center Hospital Funding: Practical Research for Innovative Cancer Control from Japan Agency for Medical Research and Development (AMED, 17ck0106352h0001) and the National Cancer Center Research and Development Fund (29-A-3). Disclosure: K. Namikawa: Honoraria from Ono Pharmaceutical, Bristol-Myers Squibb, MSD, Novartis Pharmaceutical, Toray industries, and Chugai Pharmaceutical, outside the submitted work. N. Motoi: Honoraria from Agilent Technologies, AstraZeneca, Bristol-Myers Squibb, Chugai Pharmaceutical, Leica Microsystems, MSD, Novartis Pharma, Ono Pharmaceutical, Taiho Pharmaceutical, and SRL, outside the submitted work. N. Yamazaki: Research grant and honoraria from Bristol-Myers Squibb, Ono Pharmaceutical, Novartis Pharma, and MSD. All other authors have declared no conflicts of interest." @default.
• W2770760027 created "2017-12-04" @default.
• W2770760027 creator A5000745938 @default.
• W2770760027 creator A5001893646 @default.
• W2770760027 creator A5019176236 @default.
• W2770760027 creator A5030696589 @default.
• W2770760027 creator A5031165720 @default.
• W2770760027 creator A5036690910 @default.
• W2770760027 creator A5046150870 @default.
• W2770760027 creator A5046627309 @default.
• W2770760027 creator A5047984722 @default.
• W2770760027 creator A5054855558 @default.
• W2770760027 date "2017-11-01" @default.
• W2770760027 modified "2023-09-26" @default.
• W2770760027 title "Nivolumab for patients with metastatic uveal melanoma previously untreated with ipilimumab: A single-institutional retrospective study" @default.
• W2770760027 doi "https://doi.org/10.1093/annonc/mdx667.003" @default.
• W2770760027 hasPublicationYear "2017" @default.
• W2770760027 type Work @default.
• W2770760027 sameAs 2770760027 @default.
• W2770760027 citedByCount "1" @default.
• W2770760027 countsByYear W27707600272019 @default.
• W2770760027 crossrefType "journal-article" @default.
• W2770760027 hasAuthorship W2770760027A5000745938 @default.
• W2770760027 hasAuthorship W2770760027A5001893646 @default.
• W2770760027 hasAuthorship W2770760027A5019176236 @default.
• W2770760027 hasAuthorship W2770760027A5030696589 @default.
• W2770760027 hasAuthorship W2770760027A5031165720 @default.
• W2770760027 hasAuthorship W2770760027A5036690910 @default.
• W2770760027 hasAuthorship W2770760027A5046150870 @default.
• W2770760027 hasAuthorship W2770760027A5046627309 @default.
• W2770760027 hasAuthorship W2770760027A5047984722 @default.
• W2770760027 hasAuthorship W2770760027A5054855558 @default.
• W2770760027 hasBestOaLocation W27707600271 @default.
• W2770760027 hasConcept C121608353 @default.
• W2770760027 hasConcept C126322002 @default.
• W2770760027 hasConcept C143998085 @default.
• W2770760027 hasConcept C167135981 @default.
• W2770760027 hasConcept C2775832928 @default.
• W2770760027 hasConcept C2776694085 @default.
• W2770760027 hasConcept C2777658100 @default.
• W2770760027 hasConcept C2777701055 @default.
• W2770760027 hasConcept C2778822529 @default.
• W2770760027 hasConcept C2779984678 @default.
• W2770760027 hasConcept C2780030458 @default.
• W2770760027 hasConcept C2781433595 @default.
• W2770760027 hasConcept C502942594 @default.
• W2770760027 hasConcept C71924100 @default.
• W2770760027 hasConcept C90924648 @default.
• W2770760027 hasConceptScore W2770760027C121608353 @default.
• W2770760027 hasConceptScore W2770760027C126322002 @default.
• W2770760027 hasConceptScore W2770760027C143998085 @default.
• W2770760027 hasConceptScore W2770760027C167135981 @default.
• W2770760027 hasConceptScore W2770760027C2775832928 @default.
• W2770760027 hasConceptScore W2770760027C2776694085 @default.
• W2770760027 hasConceptScore W2770760027C2777658100 @default.
• W2770760027 hasConceptScore W2770760027C2777701055 @default.
• W2770760027 hasConceptScore W2770760027C2778822529 @default.
• W2770760027 hasConceptScore W2770760027C2779984678 @default.
• W2770760027 hasConceptScore W2770760027C2780030458 @default.
• W2770760027 hasConceptScore W2770760027C2781433595 @default.
• W2770760027 hasConceptScore W2770760027C502942594 @default.
• W2770760027 hasConceptScore W2770760027C71924100 @default.
• W2770760027 hasConceptScore W2770760027C90924648 @default.
• W2770760027 hasLocation W27707600271 @default.
• W2770760027 hasOpenAccess W2770760027 @default.
• W2770760027 hasPrimaryLocation W27707600271 @default.
• W2770760027 hasRelatedWork W2519469881 @default.
• W2770760027 hasRelatedWork W2749408522 @default.
• W2770760027 hasRelatedWork W2936810997 @default.
• W2770760027 hasRelatedWork W3130253087 @default.
• W2770760027 hasRelatedWork W3212266158 @default.
• W2770760027 hasRelatedWork W4252306764 @default.
• W2770760027 hasRelatedWork W4283751238 @default.
• W2770760027 hasRelatedWork W4295837188 @default.
• W2770760027 hasRelatedWork W4306411150 @default.
• W2770760027 hasRelatedWork W4309907129 @default.
• W2770760027 hasVolume "28" @default.
• W2770760027 isParatext "false" @default.
• W2770760027 isRetracted "false" @default.
• W2770760027 magId "2770760027" @default.
• W2770760027 workType "article" @default.